These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35445657)

  • 21. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
    Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
    J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
    Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
    J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
    Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
    Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
    Wong HK; Lahdenranta J; Kamoun WS; Chan AW; McClatchey AI; Plotkin SR; Jain RK; di Tomaso E
    Cancer Res; 2010 May; 70(9):3483-93. PubMed ID: 20406973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brigatinib in
    Plotkin SR; Yohay KH; Nghiemphu PL; Dinh CT; Babovic-Vuksanovic D; Merker VL; Bakker A; Fell G; Trippa L; Blakeley JO;
    N Engl J Med; 2024 Jun; 390(24):2284-2294. PubMed ID: 38904277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four distinct ipsilateral vestibular schwannomas: A case of mosaic NF2-related schwannomatosis.
    Tunkel AE; Youner ER; Barseghyan H; Fu Y; Bhattacharya S; Bornhorst M; Monfared AS
    Am J Clin Pathol; 2024 Aug; 162(2):110-114. PubMed ID: 38527168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of multiple tumors in neurofibromatosis type 2 patients.
    Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
    Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
    Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
    Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
    Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
    J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of induced pluripotent stem cell clones derived from a patient with mosaic neurofibromatosis type 2.
    Ishi Y; Era T; Yuzawa S; Okamoto M; Sawaya R; Motegi H; Yamaguchi S; Terasaka S; Houkin K; Fujimura M
    Am J Med Genet A; 2022 Jun; 188(6):1863-1867. PubMed ID: 35178855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
    Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
    BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
    Chang LS; Oblinger JL; Smith AE; Ferrer M; Angus SP; Hawley E; Petrilli AM; Beauchamp RL; Riecken LB; Erdin S; Poi M; Huang J; Bessler WK; Zhang X; Guha R; Thomas C; Burns SS; Gilbert TSK; Jiang L; Li X; Lu Q; Yuan J; He Y; Dixon SAH; Masters A; Jones DR; Yates CW; Haggarty SJ; La Rosa S; Welling DB; Stemmer-Rachamimov AO; Plotkin SR; Gusella JF; Guinney J; Morrison H; Ramesh V; Fernandez-Valle C; Johnson GL; Blakeley JO; Clapp DW;
    PLoS One; 2021; 16(7):e0252048. PubMed ID: 34264955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas.
    Huynh DP; Mautner V; Baser ME; Stavrou D; Pulst SM
    J Neuropathol Exp Neurol; 1997 Apr; 56(4):382-90. PubMed ID: 9100669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
    Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
    J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
    Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
    Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular Biological Background of Neurofibromatosis Type 2].
    Miyawaki S; Teranishi Y; Saito N
    No Shinkei Geka; 2022 May; 50(3):572-577. PubMed ID: 35670170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
    Burns SS; Chang LS
    Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
    Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
    J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.